Heart pump vs. pills: which keeps End-Stage heart failure patients alive longer?
NCT ID NCT02592499
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests whether a mechanical heart pump called the HeartMate III (an LVAD) helps people with end-stage heart failure live longer and with fewer strokes compared to taking standard heart failure medications. About 80 adults with severe heart failure are randomly assigned to receive either the pump or optimized drug therapy. The main goal is to see who survives at two years, and the study also tracks strokes and hospitalizations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HeartMate III left ventricular assist device (LVAD)
- What this could lead to
- If successful, this could show that an LVAD improves survival and reduces disabling strokes compared to medication alone for people with end-stage heart failure.
- What could go wrong
- This is a relatively small, non-blinded study, so results may not be definitive. LVADs carry risks like infection, bleeding, and device malfunction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karolinska Univ Hospital
Stockholm, Sweden
-
Linköping Univ Hospital
Linköping, Sweden
-
Sahlgrenska Univesitetssjukhustet, Transplantationscentrum
Gothenburg, 41234, Sweden
-
Skåne University Hospital
Lund, Sweden
-
Univ Hospital of Umeå
Umeå, Sweden
-
Uppsala Univ Hospital
Uppsala, Sweden
-
Örebro Univ Hospital
Örebro, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple pump flow measure predict organ health in heart device patients?
- New study aims to simplify heart monitoring for pump patients
- Heart pump could outperform drugs in advanced heart failure
- Heart Pump's impact on failing hearts to be measured in new study
- Heart pump study tracks Long-Term survival in failing hearts
- New heart pump trial offers hope for End-Stage heart failure patients